Drugs

Papers
(The H4-Index of Drugs is 56. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Asthma and Cardiovascular Diseases: Navigating Mutual Pharmacological Interferences490
Teclistamab: First Approval465
Senaparib: First Approval276
Targeting DNA Damage Response Deficiency in Thoracic Cancers247
Spesolimab for the Treatment of Generalized Pustular Psoriasis242
Correction: New Pharmacologic Approaches to the Treatment of Bipolar Depression219
Correction: Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments191
Comment on “Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study”165
Eftrenonacog Alfa: A Review in Haemophilia B161
Acknowledgement to Referees155
Suprachoroidal Space Triamcinolone Acetonide: A Review in Uveitic Macular Edema146
Analysis of Cerebrospinal Fluid, Plasma β-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer’s Disease Using143
Epcoritamab: First Approval140
Alcohol-Associated Liver Disease: Evolving Concepts and Treatments138
Clinical Efficacy, Safety and Imaging Effects of Oral Valiltramiprosate in APOEε4/ε4 Homozygotes with Early Alzheimer’s Disease: Results of the Phase III, Randomized, Double-Blind, Placebo-Controlled,138
Vorasidenib: First Approval124
New Therapies on the Horizon for Primary Biliary Cholangitis123
Authors’ Reply to Toda: Multimodal Multidisciplinary Management of Patients with Moderate to Severe Pain in Knee Osteoarthritis: A Need to Meet Patient Expectations122
Aprocitentan: First Approval109
Aztreonam-Avibactam: A Review in the Treatment of Serious Bacterial Infections Caused by Aerobic Gram-Negative Organisms103
Efficacy and Safety of Plecanatide in Chinese Patients with Functional Constipation: A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial102
Repotrectinib: First Approval100
Ivarmacitinib Sulfate: First Approval99
Acoltremon: First Approval98
Cosibelimab: First Approval92
Influenza Vaccine Effectiveness and Progress Towards a Universal Influenza Vaccine91
Olipudase Alfa: First Approval89
QT Prolongation and Risk of Death with the Use of Methadone for Chronic Cancer and Noncancer Pain: Myths or Reality?88
Danicopan: First Approval87
Tolebrutinib: First Approval86
Advances in Pharmacotherapy for Menopausal Vasomotor Symptoms84
Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2− Early Breast Cancer83
Drugs in Development to Manage Acute Pain81
Emerging Therapies for Chronic Hepatitis B and the Potential for a Functional Cure80
Safety of Anti-osteoarthritis Medications: A Systematic Literature Review of Post-marketing Surveillance Studies79
Lenacapavir: First Approval77
Efficacy and Harms of Opioid Analgesics for Acute Pain: Overview of Systematic Reviews and Meta-analyses77
Androgenetic Alopecia: Therapy Update75
Novel Drugs for the Treatment of Pulmonary Arterial Hypertension: Where Are We Going?75
SER-109 (VOWST™): A Review in the Prevention of Recurrent Clostridioides difficile Infection72
Cancer Pain Treatment Strategies in Patients with Cancer68
Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids67
Delgocitinib 20 mg/g Cream: A Review in Chronic Hand Eczema65
Sibeprenlimab: First Approval65
Treatment of Cryptococcal Meningitis: How Have We Got Here and Where are We Going?64
Alzheimer’s Disease: Novel Targets and Investigational Drugs for Disease Modification64
Mosunetuzumab: First Approval64
Mazdutide: First Approval63
Taletrectinib: First Approval63
Situational Prevention of Migraine Attacks: Can Early Treatment Change the Conversation?63
Tovorafenib: First Approval62
Pozelimab: First Approval60
Correction to: Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes58
Correction to: Tapinarof Cream 1%: First Approval58
PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate Cancer57
Targeting Interferon Signalling in Systemic Lupus Erythematosus: Lessons Learned57
Aligning Large Language Models with Humans: A Comprehensive Survey of ChatGPT’s Aptitude in Pharmacology56
Drugs Targeting Cough Receptors: New Therapeutic Options in Refractory or Unexplained Chronic Cough56
Targeting Inflammation in Bronchiectasis56
0.11222290992737